Market Overview

UPDATE: Stifel Downgrades Geron from Hold to Sell

Related GERN
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Geron Corporation (GERN) CEO John Scarlett Hosts Analyst and Investor Event (Transcript) (Seeking Alpha)

Stifel Nicolaus' Brian Klein downgraded shares of Geron (NASDAQ: GERN) from Hold to Sell in an intraday research note.

Related to Imetelstat rests trial, the analyst said, "While management states that this is the most expedited way to derive the clinical data necessary for future company-sponsored trials, we view this development plan as flawed and sluggish." Klein believes the company should "initiate a parallel Phase 1 study of Imetelstat in myeloid leukemias in 2013, including MDS and AML, in order to provide independent confirmation of the findings from the IST, as well as to broaden the safety and efficacy database for Imetelstat in these indications. However, given management's current strategy, we have reservations on the development plan for Imetelstat..."

Shares of Geron are down nearly 10 percent to around $1.28 at last check.

Latest Ratings for GERN

Jul 2018B. Riley FBRInitiates Coverage OnBuy
Mar 2018Stifel NicolausMaintainsHoldHold
Aug 2016BTIG ResearchInitiates Coverage onNeutral

View More Analyst Ratings for GERN
View the Latest Analyst Ratings

Posted-In: Downgrades Analyst Ratings


Related Articles (GERN)

View Comments and Join the Discussion!

Latest Ratings

MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Jefferies Lowers PT on Kratos Defense & Security Solutions on Q4 EPS

ForexLive Asia Wrap: Japan Upper House Deliberations on BOJ Nominations Take Centre Stage on a Quiet Day